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Background: Primary care pharmacological management of new musculoskeletal conditions is not consistent,
despite guidelines which recommend prescribing basic analgesics before higher potency medications such as
opioids or non-steroidal inflammatory drugs (NSAIDs).
The objective was to describe pharmacological management of new musculoskeletal conditions and determine
patient characteristics associated with type of medication prescribed.
Methods: The study was set within a UK general practice database, the Consultations in Primary Care Archive (CiPCA).
Patients aged 15 plus who had consulted for a musculoskeletal condition in 2006 but without a musculoskeletal
consultation or analgesic prescription in the previous 12 months were identified from 12 general practices. Analgesic
prescriptions within two weeks of first consultation were identified. The association of socio-demographic and clinical
factors with receiving any analgesic prescription, and with strength of analgesic, were evaluated.
Results: 3236 patients consulted for a new musculoskeletal problem. 42% received a prescribed pain medication at
that time. Of these, 47% were prescribed an NSAID, 24% basic analgesics, 18% moderate strength analgesics, and 11%
strong analgesics. Increasing age was associated with an analgesic prescription but reduced likelihood of a prescription
of NSAIDs or strong analgesics. Those in less deprived areas were less likely than those in the most deprived areas to be
prescribed analgesics (odds ratio 0.69; 95% CI 0.55, 0.86). Those without comorbidity were more likely to be prescribed
NSAIDs (relative risk ratios (RRR) compared to basic analgesics 1.89; 95% CI 0.96, 3.73). Prescribing of stronger analgesics
was related to prior history of analgesic medication (for example, moderate analgesics RRR 1.88; 95% CI 1.11, 3.10).
Conclusion: Over half of patients were not prescribed analgesia for a new episode of a musculoskeletal condition, but
those that were often received NSAIDs. Analgesic choice appears multifactorial, but associations with age, comorbidity,
and prior medication history suggest partial use of guidelines.
Keywords: Primary health care, Analgesia, Musculoskeletal, Medical recordsBackground
Guidelines for the management of painful musculoskeletal
conditions advocate a holistic approach incorporating
education, psychological, physical, and surgical inter-
ventions administered in a step-wise fashion [1,2]. This
comprehensive strategy is, however, underpinned by
the use of analgesic medications which play a central
role in the management of musculoskeletal conditions* Correspondence: k.p.jordan@keele.ac.uk
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unless otherwise stated.[3]. In addition, musculoskeletal pain has financial con-
sequences for both the patients and their employers in
terms of sickness absence and lost productivity [4]. For
example, the direct health care cost of back pain in the
UK in 1998 was estimated to be around £1.6 billion
with the cost of informal care and productivity losses
related to back pain totalling £10 billion [4]. Currently,
there is evidence that analgesic management still needs
considerable improvement [5] and consequently, a better
understanding of analgesic use is essential if we are to im-
prove this element of musculoskeletal pain management.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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health care professionals guidance on the use of analgesia
in low back pain that is equally applicable to musculoskel-
etal conditions in general [1]. This advice constituted an
analgesic ladder, whereby doctors were encouraged to use
basic analgesics in the first instance (e.g. paracetamol),
then step up to using non-steroidal anti-inflammatories if
basic analgesics did not control the pain, and where
appropriate as a third step, use opioid analgesics such as
codeine. The WHO guidance is explicit in its use of opi-
oids as a third line treatment because of concerns relating
to the risks of addiction. This advice has been widely
disseminated and is also currently reflected in the NICE
guidelines for managing osteoarthritis [2].
Despite guidance advocating similar approaches for neck
and low back pain, their management strategies have been
shown to be different in terms of the analgesics prescribed
and other therapies [6]. Whilst even with the introduction
of guidelines, analgesic prescribing in patients with low
back pain has not been shown to change [7]. Other influ-
ences than guidelines may affect a GP’s decision making,
for example GPs may feel a more potent analgesic in the
first instance is more appropriate than basic analgesics if
the patient presents with severe and debilitating pain des-
pite risk of side effects. The extent and type of analgesic
prescribing in new episodes of musculoskeletal pain is
unclear, as is how it varies by site of problem (for example,
knee, hip, back), or whether there are characteristics of
the patient which are associated with the decision to pre-
scribe analgesia and the type of analgesia prescribed.
The primary objectives of this study were therefore, to
describe the analgesics that primary care clinicians pre-
scribe when a patient consults with a new episode of a
musculoskeletal condition, and to determine socio-demo
graphic and clinical factors associated with being pre-
scribed medication and type of medication.
Methods
Population
This was a retrospective study based in the Consultations
in Primary Care Archive (CiPCA). CiPCA is a high quality
primary care database, giving comparable musculoskeletal
consultation prevalence to national primary care databases
[8,9]. Approval to download and store anonymised medical
record information for research was granted by the North
Staffordshire Research Ethics Committee. All general
practices participating in CiPCA inform their registered
patients that their anonymised records will be used in this
way. Patients are offered the opportunity to withdraw their
records from inclusion in CiPCA. In the UK, the majority
of the population are registered with a general practice, and
this is normally the first point of access to the National
Health Service. Data was used from 12 general practices
which contributed data for the period 2004–2006.Patients aged 15 and over were included if they con-
sulted for a musculoskeletal condition in 2006, with no
musculoskeletal consultation and no prescribed analgesic
medication for the 12 months preceding their 2006
consultation. Musculoskeletal conditions were defined
using Read Codes based on a previously derived set of
codes [10]. Read codes are a commonly used system for
recording morbidity in UK primary care. Musculoskeletal
consultations were identified as those recorded with any
Read code within Chapter N “Musculoskeletal and con-
nective tissues diseases” or with Read codes considered by
consensus of 2 GPs to be musculoskeletal in nature within
Chapters R “Symptoms, Signs and Ill-defined conditions”,
and 1 "History/Symptoms". Four GPs then allocated all
such Read codes to individual body regions (e.g. back,
knee) or unspecified if no region could be allocated.
“Unspecified” problems tended to be codes where either
no region was described in the associated Read Term (e.g.
the term simply specified “arthralgia”) or the problem
covered more than one region (e.g. “generalised osteo-
arthritis”). Injuries were excluded in order to focus on
musculoskeletal conditions which have no obvious aeti-
ology and have the potential for becoming chronic
complaints. In the majority of cases injuries tend to be
self-limiting and of relatively short duration. The inclusion
criterion is based on the assumption that any patient who
does not consult for a musculoskeletal condition and does
not receive prescribed analgesic medication for 12 months
does not have a chronic or persistent musculoskeletal
problem that is currently considered by the patient as
troublesome [11].
Pain medication
In the United Kingdom (UK) there are over 300 pre-
scribable analgesic formulations available to general
practitioners (GPs) [12]. Bedson and colleagues, using GPs
in a consensus exercise, derived a hierarchical analgesic
categorisation where all analgesic formulations were cate-
gorised into six groups according to equipotency levels
when treating varying levels of perceived pain as shown in
Figure 1 [13]. Group 1 comprises basic analgesics such as
paracetamol. Groups 2–4 are made up of increasingly
potent opioids either alone or in combination with para-
cetamol. Group 2 includes weak opioids (for example,
codeine 8 mg). Group 3 includes moderate opioids (for
example, codeine 15 mg). Group 4 includes strong opioids
(for example, codeine 30 mg). Group 5 contains very
strong opioids (morphine and oxycodone). Group 6 com-
prises non-steroidal anti-inflammatory drugs (NSAIDs)
which the consensus exercise did not rank in the potency
ladder but were considered as an adjunct to analgesic
prescribing.
For this study, due to the low prevalence of prescrip-
tion of very strong opioids [13] and to aid interpretation,
Basic Analgesics Weak-Moderate Analgesics Strong analgesics
NSAIDs Including Ibuprofen (600mg)
Weak combination opioids
Codeine (8mg) + Paracetamol
Dihydrocodeine (10mg) +
Paracetamol
Tramadol (37.5mg) + Paracetamol
Moderate combination opioids + 
opioids
+/- Paracetamol 
Codeine (15mg)
Dihydrocodeine (20mg)
Buprenorphine (5-10mcg/hr + 
200mcg)
Co-proxamol 
Codeine (20mg) + Ibuprofen 
(300mg)
Nefopam
Strong combination 
opioids + opioids
+/- Paracetamol 
Codeine (30mg)
Dihydrocodeine (30mg)
Buprenorphine 
(>20 mcg/hr + 400mcg)
Tramadol (50mg)
Pentazocine 
Pethidine 
Meptazinol
Very strong single 
opioids
Morphine
Oxycodone
Paracetamol
Ibuprofen (200-400mg)
Aspirin (600mg)
Capsaicin
Topical NSAIDs
NSAIDs including Ibuprofen (600mg) 
+ COX 2    
Figure 1 Revised hierarchical analgesic categorisation model for prescribing analgesics and NSAIDs in primary care. Modified version of
that published in Bedson J, Belcher J, Martino OI et al. The effectiveness of national guidance in changing analgesic prescribing in primary care
from 2002 to 2009: an observational database study, European Journal of Pain, 2013;17:434–443, with permission of John Wiley and Sons.
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combining weak and moderate combination opioids (weak-
moderate analgesics), and strong combination opioids with
very strong single opioids (strong analgesics). Pain medica-
tion was deemed as being related to a musculoskeletal
consultation if it was prescribed on the same day as the
consultation, or within 14 days of that consultation. This
was to allow for patients to take up a ‘delayed’ prescription
for analgesics that the GP offered should the condition
not improve.
Socio-demographic and clinical factors
Factors evaluated for their association with pain medica-
tion prescription on first consultation included the patient’s
age, gender, co-morbidity, region of pain, previous consult-
ation for musculoskeletal conditions, analgesic medicationhistory, neighbourhood deprivation, registered practice,
and staff consulted. The age of the patient was calcu-
lated as of 1st July 2006 and grouped into the following
categories: 15–29, 30–44, 45–59, 60–74, and 75+.
Neighbourhood deprivation was based on the Index of
Multiple Deprivation 2007. This is linked to the post-
codes of patient addresses [14]. The deprivation ranks
range from 1 to 32482, with 1 being the most deprived
neighbourhood and 32482 least deprived in England.
This variable was categorised into 3 levels with pa-
tients in the lower third based on deprivation rank
being the most deprived, the middle third moderately
deprived and the top third least deprived. The staff
member consulted was categorised into GPs and all
other medical staff (such as practice nurses and nurse
practitioners).
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foot and ankle, arm (hand, wrist, arm, elbow and upper
limb), shoulder, and other or unspecified. The specified
areas are the most common locations of musculoskeletal
pain [15]. Identification of pain region used a previously
derived classification [10]. Previous consultation for a mus-
culoskeletal problem was defined as having a recorded
musculoskeletal consultation in the period 12 to 24 months
before the baseline musculoskeletal consultation. Similarly,
previous pain medication was defined as receiving any
prescribed pain medication 12 to 24 months before the
baseline musculoskeletal consultation. These variables give
a brief medical history of the patient which clinicians may
consider in deciding whether to give medication or not
and which medication to prescribe [16].
Co-morbidity was defined as the presence of one or
more specified disorders or diseases in the period 0–24
months before the baseline musculoskeletal consultation.
The specific comorbidities were diabetes, chronic obstruct-
ive pulmonary disease (COPD), depression, cardiovascular
disease, chronic kidney disease, gastro-intestinal, and neo-
plasm. These are long term comorbidities which clinicians
take into consideration when deciding which type of
analgesia to prescribe [16].
Statistical analysis
Multilevel logistic regression was used to evaluate the
associations of being prescribed any pain medication on
first consultation with patient and practice characteris-
tics. Levels within the multilevel model were patient
(level 1) within practice (level 2). Results are presented
as odds ratios (OR) with 95% confidence intervals. Both
adjusted and unadjusted odds ratios for the patient char-
acteristics are reported.
A second analysis was then performed on only those
receiving a pain medication. A multilevel multinomial
logistic regression model with the analgesic group as the
dependent variable was used to assess associations of
patient and practice characteristics with type of analgesic
received. The reference category was group 1 (basic
analgesics). Results are reported as relative risk ratios
(RRR) with 95% confidence intervals. All models were
evaluated using a 5% statistical significance level with
no adjustment for multiple testing using the statistical
package Stata.
Results
New consulters for musculoskeletal problems
In 2006, there were 83,875 patients aged 15 and over
registered at the 12 practices. 3236 (386 per 10,000)
patients were identified as having a new consultation for
a musculoskeletal problem in 2006. The mean age of
these 3236 patients was 43.1 years (SD 15.8), and 1916
(59%) were male (Table 1).The back was the most common site of the musculo-
skeletal problem (26%), followed by the knee (11%).
Least commonly affected was the hip (6%), with other or
unspecified regions accounting for 26% (Table 1). 13%
had a recent history of consulting for a musculoskeletal
problem, albeit not within the previous 12 months, and
16% had received pain medication 12–24 months before
their 2006 consultation.
Pain medication prescriptions
1344 (42%) patients received prescribed pain medication
within 14 days of their new musculoskeletal consultation
(Table 1). Of those who received prescribed pain medi-
cation, 24% received basic analgesics, 18% weak or mod-
erate analgesics, 11% strong analgesics and 47% NSAIDs
(Table 2). Socio-demographic and clinical characteristics
of those prescribed the different types of pain medica-
tion are detailed in Table 2.
Factors associated with prescription of analgesics
The associations of prescribing any pain medication with
socio-demographic and clinical factors are shown in
Table 3. There was significant practice variation in the
decision to prescribe (range across practices of 30% to 57%
of patients receiving analgesics) with variation between
practices accounting for 9% of unexplained variation in
patients being prescribed analgesics in the multivariable
model.
Compared to the 30–44 year old age group, the odds
of being prescribed pain medication on first consultation
were significantly less in those aged 15 to 29 (adjusted
OR 0.69; 95% CI 0.56, 0.85) but higher in those aged 45
to 59 (OR 1.23; 95% CI 1.02, 1.49), 60 to 74 (OR 1.51;
95% CI 1.17, 1.95), and those aged over 75 (OR 2.28;
95% CI 1.49, 3.49). Those in the least deprived areas
were least likely to receive a pain medication prescrip-
tion (OR 0.69; 95% CI 0.55, 0.86). Pain medication was
most likely to be prescribed for those with pain in the
back; however, no difference was apparent between those
with shoulder and back problems. Those who had re-
ceived prescribed analgesics in the past were more likely
to be prescribed pain medication at this new consult-
ation (OR 1.24; 95% CI 1.01, 1.54).
There were no significant relationships with comorbidity,
gender or whether the patient saw a GP or other medical
staff.
Factors associated with type of analgesics
In the 1344 patients prescribed analgesics, there was
wide variation between practices in type of analgesic pre-
scribed. Variation between practices accounted for 27% of
all remaining variation in type of medication prescribed in
the multivariable model.
Table 1 Socio-demographic and clinical characteristics of
patients with new consulting episode of musculoskeletal
pain in 2006
Analgesic received
N Column % n Row %
Total 3236 - 1344 42
Age (years)
15-29 710 22 224 32
30-44 1081 33 448 41
45-59 963 30 428 44
60-74 374 12 181 48
75+ 108 3 63 58
Gender
Females 1320 41 551 42
Males 1916 59 793 41
Previous musculoskeletal
consultationa
Yes 413 13 163 39
No 2823 87 1181 42
Previous analgesic
prescriptionb
Yes 512 16 244 48
No 2724 84 1100 40
Region of Pain
Back 838 26 465 55
Knee 341 11 144 42
Hip 203 6 68 33
Foot and Ankle 223 7 94 42
Arm 314 10 105 33
Shoulder 245 8 129 53
Neck 218 7 93 43
Other/unspecified 854 26 246 29
Co-morbidityc
Yes 119 4 63 53
No 3117 96 1281 41
Deprivation
Most 1430 44 624 44
Moderate 1263 39 508 40
Least 543 17 212 39
Staff category
GPs 2616 81 1117 43
Other 620 19 227 37
Practice
1 254 8 79 31
2 224 7 78 35
3 219 7 77 35
4 253 8 76 30
Table 1 Socio-demographic and clinical characteristics of
patients with new consulting episode of musculoskeletal
pain in 2006 (Continued)
5 161 5 59 37
6 283 9 115 41
7 420 13 241 57
8 324 10 143 44
9 288 9 130 45
10 327 10 166 51
11 143 4 57 40
12 340 11 123 36
N = Total number of patients for each category, n = number of patients
prescribed analgesic per category, Col. % = N/3236, Row % = n/N for each row.
amusculoskeletal consultation 12–24 months before their 2006 consultation.
bprescribed pain medication 12–24 months before their 2006 consultation.
cdiabetes, chronic obstructive pulmonary disease (COPD), depression,
cardiovascular disease, chronic kidney disease, gastro-intestinal, or neoplasm.
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and clinical factors with type of analgesics in those
prescribed analgesics. Compared to those aged 30–44,
patients aged 15–29 were more likely to receive basic
analgesics than weak-moderate analgesics, strong analge-
sics or NSAIDs. In the case of NSAIDs for example, for
patients aged 15–29 the adjusted RRR was 0.30 (95% CI
0.20, 0.46) compared to the 30–44 age group. A similar
decreased chance of NSAID prescription was also evi-
dent in those aged over 60 (for example, aged 75 and
above, RRR 0.05; 95% CI 0.02, 0.13). Females were more
likely than males to be prescribed weak-moderate anal-
gesics compared to basic analgesics (RRR 1.45; 95% CI
1.02, 2.09). A previous history of analgesic prescription
was associated with the prescribing of stronger medica-
tion compared to basic analgesics (for example, weak-
moderate analgesic, RRR 1.88; 95% CI 1.11, 3.10). Strong
analgesics were less likely to be prescribed than basic
analgesics to those living in the least deprived areas
(RRR 0.45; 95% CI 0.23, 0.88). There was a marginally
non-significant increased likelihood of being prescribed
NSAIDs if the patient did not have comorbidity (RRR
1.89; 95% CI 0.96, 3.73).
Those with back pain were more likely to be prescribed
weak-moderate analgesics, strong analgesics and NSAIDs
than basic analgesics compared to those presenting with
musculoskeletal problems in other regions. Those who
were seen by GPs were more likely to be prescribed strong
analgesics than basic analgesics (RRR 1.74; 95% CI 1.01,
3.02).
Discussion
This study has shown that more than half the patients
consulting for a new episode of a musculoskeletal condi-
tion were not prescribed pain medication. Of those who
were, most commonly NSAIDs were prescribed, with
Table 2 Socio-demographic and clinical characteristics of patients prescribed each group of analgesic
Pain medication prescribed
Basic analgesic Weak/moderate analgesic NSAIDs Strong analgesic
n % n % n % n %
Total 321 24 239 18 637 47 147 11
n % n % n % n %
Age (years)
15-29 85 26 28 12 96 15 15 10
30-44 73 23 66 28 250 39 59 40
45-59 79 24 77 32 221 35 51 35
60-74 53 17 44 18 65 10 19 13
75+ 31 10 24 10 5 1 3 2
Gender
Females 137 43 118 49 230 36 66 45
Males 184 57 121 51 407 64 81 55
Previous musculoskeletal consultationa
Yes 33 10 28 12 83 13 19 13
No 288 90 211 88 554 87 128 87
Previous analgesic prescriptionb
Yes 40 12 49 21 127 20 28 19
No 281 88 190 79 510 80 119 81
Region of Pain
Back 64 20 114 48 203 32 84 57
Knee 44 14 11 5 84 13 5 3
Hip 10 3 13 5 38 6 7 5
Foot and Ankle 26 8 10 4 54 9 4 3
Arm 41 13 9 4 54 8 1 1
Shoulder 34 10 14 6 71 11 10 7
Neck 17 5 15 6 44 7 17 12
Other/unspecified 85 26 54 22 89 14 19 13
Co-morbidityc
Yes 20 6 13 5 22 3 8 5
No 301 94 226 95 615 97 139 95
Deprivation
Most 146 46 123 52 277 43 78 53
Moderate 120 37 82 34 254 40 52 35
Least 55 17 34 14 106 17 17 12
Staff category
GPs 273 85 210 88 523 82 111 76
Other 48 15 29 12 114 18 36 24
Total % = n/1344, % = n/n.
amusculoskeletal consultation 12–24 months before their 2006 consultation.
bprescribed pain medication 12–24 months before their 2006 consultation.
cdiabetes, chronic obstructive pulmonary disease (COPD), depression, cardiovascular disease, chronic kidney disease, gastro-intestinal, or neoplasm.
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There appears to be restricted early use of stronger medi-
cation with strong opioids being prescribed for only
one in ten new musculoskeletal patients prescribed painmedication. Patient age, deprivation, body region of pain,
comorbidity and previous analgesic prescriptions were
associated with prescribing behaviour and there was
extensive practice variation.
Table 3 Associations with prescription of any analgesic at new consultation for musculoskeletal pain
Model OR [95% CI]
Fixed effects Unadjusted Adjusted Adjusted p-value
Age Group
30-44 1.00 1.00 -
15-29 0.65 [0.53, 0.80] 0.69 [0.56, 0.85] <0.001
45-59 1.12 [0.94, 1.34] 1.23 [1.02, 1.49] 0.025
60-74 1.28 [1.01, 1.64] 1.51 [1.17, 1.95] 0.002
75+ 1.85 [1.23, 2.78] 2.28 [1.49, 3.49] <0.001
Gender
Male 1.00 1.00 -
Female 1.00 [0.87, 1.15] 1.02 [0.88, 1.19] 0.780
Previous musculoskeletal consultationa
No 1.00 1.00 -
Yes 0.89 [0.72, 1.09] 0.83 [0.66, 1.05] 0.119
Previous analgesic prescriptionb
No 1.00 1.00 -
Yes 1.24 [1.03, 1.49] 1.24 [1.01, 1.54] 0.045
Pain Region
Back 1.00 1.00 -
Knee 0.59 [0.46, 0.77] 0.56 [0.43, 0.72] <0.001
Hip 0.38 [0.27, 0.52] 0.35 [0.25, 0.49] <0.001
Foot and Ankle 0.55 [0.40, 0.74] 0.52 [0.38, 0.71] <0.001
Arm 0.40 [0.30, 0.54] 0.39 [0.29, 0.53] <0.001
Shoulder 0.90 [0.67, 1.20] 0.81 [0.60, 1.08] 0.155
Neck 0.58 [0.43, 0.79] 0.57 [0.42, 0.78] <0.001
Other/unspecified 0.32 [0.26, 0.39] 0.29 [0.24, 0.37] <0.001
Comorbidityc
Yes 1.00 1.00 -
No 0.64 [0.44, 0.92] 0.77 [0.52, 1.13] 0.217
Deprivation
Most 1.00 1.00 -
Medium 0.85 [0.73, 1.01] 0.80 [0.67, 0.95] 0.012
Least 0.77 [0.63, 0.95] 0.69 [0.55, 0.86] 0.001
Staff category
Other 1.00 1.00 -
GP 0.85 [0.70, 1.02] 0.85 [0.69, 1.04] 0.108
Random effect VARIANCE
Practice 0.08 [0.03, 0.21] 0.09 [0.03, 0.23] <0.001
amusculoskeletal consultation 12–24 months before their 2006 consultation.
bprescribed pain medication 12–24 months before their 2006 consultation.
cdiabetes, chronic obstructive pulmonary disease (COPD), depression, cardiovascular disease, chronic kidney disease, gastro-intestinal, or neoplasm.
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musculoskeletal pain received an analgesic. A previous
study of those aged over 50 consulting in primary care
for musculoskeletal pain, and who had not consulted in
the previous 30 days, also reported that less than halfwere prescribed analgesics [17] and this is also similar to
findings from studies focussed on neck and back pain
[6,7] and on osteoarthritis [18]. It is feasible that GPs
may be following guidelines that recommend the early
use of exercise and other physical therapies with or
Table 4 Associations with type of analgesia prescribed at new consultation for musculoskeletal pain in those
prescribed an analgesic
Model RRR [95% CI]
Fixed effects Weak-moderate analgesics Strong analgesics NSAIDs
n Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Age Group
30-44 224 1.00 1.00 1.00 1.00 1.00 1.00
15-29 448 0.33 [0.19, 0.57] 0.32 [0.18, 0.57] 0.20 [0.10, 0.38] 0.20 [0.10, 0.40] 0.30 [0.20, 0.45] 0.30 [0.20, 0.46]
45-59 428 1.07 [0.67, 1.17] 1.32 [0.81, 2.15] 0.79 [0.48, 1.30] 1.04 [0.62, 1.78] 0.81 [0.56, 1.18] 0.83 [0.54, 1.22]
60-74 181 0.87 [0.51, 1.46] 1.19 [0.67, 2.13] 0.42 [0.22, 0.78] 0.71 [0.35, 1.42] 0.34 [0.21, 0.53] 0.35 [0.22, 0.57]
75+ 63 0.76 [0.40, 1.47] 1.01 [0.50, 2.05] 0.11 [0.03, 0.37] 0.18 [0.05, 0.64] 0.04 [0.02, 0.11] 0.05 [0.02, 0.13]
Gender
Male 793 1.00 1.00 1.00 1.00 1.00 1.00
Female 551 1.32 [0.94, 1.86] 1.45 [1.02, 2.09] 1.10 [0.74, 1.62] 1.31 [0.85, 2.01] 0.77 [0.58, 1.01] 0.95 [0.70, 1.28]
Previous musculoskeletal
consultationa
No 1181 1.00 1.00 1.00 1.00 1.00 1.00
Yes 163 1.10 [0.64, 1.90] 0.86 [0.47, 1.58] 1.23 [0.67, 2.27] 0.98 [0.49, 1.95] 1.24 [0.80, 1.93] 0.93 [0.57, 1.54]
Previous analgesic prescriptionb
No 1100 1.00 1.00 1.00 1.00 1.00 1.00
Yes 244 1.64 [1.03, 2.61] 1.88 [1.11, 3.10] 1.49 [0.88, 2.56] 1.72 [0.94, 3.16] 1.58 [1.07, 2.35] 1.74 [1.11, 2.71]
Pain Region
Back 465 1.00 1.00 1.00 1.00 1.00 1.00
Knee 144 0.13 [0.06, 0.26] 0.11 [0.05, 0.23] 0.08 [0.03, 0.21] 0.08 [0.03, 0.23] 0.54 [0.34, 0.87] 0.65 [0.40, 1.08]
Hip 68 0.72 [0.29, 1.77] 0.61 [0.24, 1.55] 0.53 [0.19, 1.48] 0.62 [0.21, 1.81] 1.18 [0.55, 2.56] 1.59 [0.71, 3.55]
Foot and Ankle 94 0.21 [0.09, 0.47] 0.17 [0.07, 0.39] 0.11 [0.04, 0.35] 0.10 [0.03, 0.32] 0.63 [0.37, 1.12] 0.61 [0.34, 1.10]
Arm 105 0.12 [0.05, 0.26] 0.10 [0.05, 0.23] 0.02 [0.00, 0.14] 0.02 [0.00, 0.13] 0.40 [0.24, 0.67] 0.40 [0.24, 0.69]
Shoulder 129 0.22 [0.11, 0.45] 0.18 [0.09, 0.37] 0.21 [0.10, 0.47] 0.18 [0.08, 0.40] 0.62 [0.38, 1.05] 0.56 [0.33, 0.96]
Neck 93 0.49 [0.23, 1.06] 0.50 [0.23, 1.12] 0.76 [0.35, 1.61] 0.83 [0.37, 1.84] 0.81 [0.43, 1.54] 0.82 [0.42, 1.62]
Other/unspecified 246 0.36 [0.22, 0.57] 0.32 [0.20, 0.53] 0.17 [0.10, 0.32] 0.18 [0.10, 0.34] 0.34 [0.22, 0.51] 0.38 [0.25, 0.59]
Comorbidityc
Yes 63 1.00 1.00 1.00 1.00 1.00 1.00
No 1281 1.18 [0.57, 2.44] 1.49 [0.68, 3.26] 1.18 [0.50, 2.76] 1.40 [0.56, 3.53] 1.89 [1.30, 3. 57] 1.89 [0.96, 3.73]
Deprivation
Most 624 1.00 1.00 1.00 1.00 1.00 1.00
Medium 508 0.85 [0.58, 1.26] 0.75 [0.49, 1.13] 0.85 [0.58, 1.33] 0.76 [0.47, 1.22] 1.17 [0.86, 1.61] 1.19 [0.85, 1.67]
Least 212 0.74 [0.44, 1.23] 0.58 [0.33, 1.01] 0.58 [0.31, 1.09] 0.45 [0.23, 0.88] 1.02 [0.68, 1.54] 1.00 [0.64, 1.56]
Staff category
Other 227 1.00 1.00 1.00 1.00 1.00 1.00
GP 1117 0.79 [0.47, 1.04] 0.81 [0.47, 1.39] 1.86 [1.12, 3.09] 1.74 [1.01, 3.02] 1.25 [0.84, 1.86] 1.17 [0.77, 1.79]
Random effect Adjusted VARIANCE [standard error]
Practice 0.27 [0.13]
amusculoskeletal consultation 12–24 months before their 2006 consultation.
bprescribed pain medication 12–24 months before their 2006 consultation.
cdiabetes, chronic obstructive pulmonary disease (COPD), depression, cardiovascular disease, chronic kidney disease, gastro-intestinal, or neoplasm.
Bold indicates p < 0.05 in adjusted analysis. Reference is prescription of basic analgesic.
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determine if this is happening [1,19].
The WHO advice relating to managing low back pain,
one of the commonest forms of musculoskeletal pain
treated in primary care [1], suggested that clinicians
should administer simple analgesics like paracetamol
for pain relief prior to considering using oral NSAIDs,
and then opioids if pain is not controlled by the previ-
ous analgesic group. Basic analgesics are available over
the counter without prescription, and patients first seen
in primary care may already be using these medications.
Prescribing of NSAIDs may reflect clinicians feeling
that the severity of their patients’ complaints warrants
an analgesic stronger than that available without
prescription. If a basic analgesic has already been used,
the next step in the WHO analgesic ladder is to use
NSAIDs, followed by weak opioids and subsequently
stronger ones. In our study the most potent opioid
medications were indeed prescribed less than basic
analgesics on first consultation. This may also reflect
other elements of the clinician’s decision making process,
which takes into account the adverse side effects that
patients are more likely to experience when prescribed
higher potency drugs. Starting at a lower potency mini-
mises this risk [16,20,21]. Rather than a patient’s previous
consultation history for musculoskeletal conditions, it
appeared that the clinician’s knowledge of previous
analgesic medication affected their prescribing. A patient
with a past history of prescribed pain medication was
more likely to receive any analgesic and, particularly,
stronger analgesic, as has been shown previously [17].
Clinicians will generally ask the patient about their
medication use prior to consultation [20]. The more
potent analgesic may subsequently be used if the patient’s
experience of pain relief with the previous basic analgesic
was unsatisfactory.
Clinicians appear to consider patient age when choosing
to prescribe a pain medication or not, and what level of
analgesic potency to prescribe. In our study, those aged
over 75 were twice as likely to receive pain medication as
younger age groups, but were less likely to be prescribed
NSAIDs. This finding is in keeping with current advice on
NSAID use in older patients who might be considered
more likely to experience adverse effects such as renal tox-
icity [16,22] and gastrointestinal haemorrhage [23,24] with
NSAIDs. Stronger opioids were less likely to be used in
those aged over 75, a finding that has also been described
previously [25-28]. This would make clinical sense since
using these more potent opioid type drugs in the elderly
has been associated with increased rates of falls and bone
fractures [21]. Comorbidity was linked to a lower likeli-
hood of being prescribed NSAIDs which also reflects the
possibility clinicians are avoiding these drugs in patients
more vulnerable to side effects [29]. However, this findingwas non-significant and the prevalence of our selected
comorbidities in this group with new musculoskeletal
problems was low. Further research is needed on the ex-
tent to which comorbidity influences analgesic prescribing.
Younger adults (15–29) were more likely to be pre-
scribed basic analgesics, perhaps reflecting the less severe
nature of pain in younger people with musculoskeletal
problems [30]. Female patients were more likely to be pre-
scribed weak or moderate opioids over basic analgesics.
They also had a non-significant higher likelihood of re-
ceiving stronger analgesics. Females are often perceived as
experiencing more pain than males and females have been
shown to be better than males at communicating their
pain [3,20,31,32], which may influence the decision to pre-
scribe more potent medication than basic analgesics.
Patients from the most deprived areas were more likely
to be prescribed pain medication than patients from
medium and least deprived areas and be prescribed stron-
ger analgesics. Social characteristics such as neighbour-
hood level of deprivation have an additional effect on pain
[33,34]. The level of pain is associated with emotional dis-
tress, low social support and low social participation that
may be more common in deprived areas [20,33]. Further,
patients in more deprived areas may rely on prescribed
medication even for pain that can be eased with over the
counter medications as prescriptions are free for low
income and older patients in the UK [35]. Patients from
least deprived areas may prefer to purchase over the
counter medications as they pay for their prescriptions,
a finding shown previously for over the counter use of
aspirin in cardiovascular diseases [36].
Patients presenting with back problems were most
likely to receive pain medication and to receive stronger
analgesics. Back pain limits the functional reach of limbs
and the ability to rotate the trunk repetitively which is
essential for mobility, and results in restrictions on indi-
viduals’ social and physical activities and a substantial
impact on their life style [32]. Clinicians may be more
likely to perceive back pain as limiting in the day to day
activities that a person has to perform hence consider
there is a greater need to prescribe stronger pain medi-
cation for back pain. Additionally, clinicians’ perceptions
of the handicap that pain causes may vary across different
body regions. For example back, knee and hip pain may
be perceived as being debilitating in terms of mobility,
whilst shoulder, wrist and hand pain limit daily activities
such as washing, cooking, and cleaning [15,37,38]. This
may be reflected in some body locations being associated
with prescription of more potent analgesics than others.
The findings of this study are limited by the fact that it
was based in a regional dataset and therefore might not
be reflective of analgesic prescribing in other areas of
the United Kingdom. However, the data used in the
study is drawn from a data set, CiPCA, which gave
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ditions as the larger national databases [8]. We did not
evaluate the prescribing of pain medication by specific
diagnoses. However, patients often present to primary care
with a regional musculoskeletal symptom, such as back or
knee pain, which is not initially labelled with a diagnosis.
Region specific management is common in primary care,
for example for back pain [1], and GPs may prefer to work
with a regional pain label than a complex diagnostic label.
Patients were selected over a 12 month consultation
period and the inclusion criteria may include patients with
musculoskeletal episodes with a periodicity more than
12 months and those who have been taking over the coun-
ter medications or receiving other care. Their previous
consultation and medication prescription history may not
be a true reflection of the starting point of the pharmaco-
logical management of a musculoskeletal condition. How-
ever the inclusion criteria ensures that it is reasonable to
consider the patients as having no chronic pain prior to
consulting as chronic pain is defined as pain lasting more
than three months [5,11]. Clinicians consider multiple
factors in deciding the medication and appropriate dose
[16,20,39,40] and there may be other unmeasured vari-
ables such as other contraindications which may influence
prescribing. Pain severity, weight, alcohol misuse and eth-
nicity might also impact on prescription of pain medica-
tion [41] and these are not evaluated in this analysis.
Conclusion
This study highlights that age, deprivation, body region
of pain, comorbidity and previous analgesic prescriptions
are associated with analgesic prescribing in primary care
when treating patients with a new consulting episode of a
musculoskeletal condition. There appears to be a clinically
sensible use of these painkillers, in as much as analgesics
such as NSAIDs and opioids are less likely to be used in
groups that may be more vulnerable to potential side
effects. Prescribing also varies depending upon the region
of pain being treated. The prescribing characteristics may
follow the WHO analgesic ladder of prescribing since
there is a restricted use of stronger analgesics at first
consultation. However, further research into the pharma-
cological management of musculoskeletal pain is required
to determine if these patterns of prescribing represent the
optimum management pathways when managing muscu-
loskeletal conditions.
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